Mark Kong CFA

Stock Analyst at DBS

(1.25)
# 3,825
Out of 4,670 analysts
24
Total ratings
35.3%
Success rate
-1.5%
Average return

Stocks Rated by Mark Kong CFA

Innovent Biologics, Inc.
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $144.00
Current: $102.40
Upside: +40.63%
Sino Biopharmaceutical Limited
May 20, 2026
Initiated Coverage: Buy
Price Target: $6.50
Current: $5.60
Upside: +16.18%
BeOne Medicines AG
May 7, 2026
Maintained: Buy
Price Target: $290.00
Current: $228.00
Upside: +27.19%
Consun Pharmaceutical Group Limited
Mar 27, 2026
Maintained: Buy
Price Target: $22.00$26.00
Current: $13.60
Upside: +91.18%
Laekna, Inc.
Mar 20, 2026
Maintained: Buy
Price Target: $24.16
Current: $6.05
Upside: +299.34%
Sinopharm Group Co. Ltd.
Dec 12, 2024
Upgraded: Buy
Price Target: $25.00
Current: $16.65
Upside: n/a
China Resources Medical Holdings Company Limited
Oct 24, 2024
Maintained: Buy
Price Target: $7.50
Current: $2.61
Upside: n/a
Sanofi
Oct 11, 2024
Maintained: Buy
Price Target: n/a
Current: $45.85
Upside: n/a
Vertex Pharmaceuticals
Oct 8, 2024
Maintained: Hold
Price Target: n/a
Current: $548.05
Upside: n/a
AbbVie
Sep 13, 2024
Maintained: Hold
Price Target: n/a
Current: $264.96
Upside: n/a
Maintained: Buy
Price Target: n/a
Current: $145.13
Upside: n/a